Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
Year in Review
TRANSFORM Primary Analysis and Indirect Comparison of Liso-cel to Axi-cel
LBCL 2022 - Year in Review
Dr Jeremy S. Abramson analyzes data from the primary analysis of the TRANSFORM study and a matching-adjusted indirect comparison of liso-cel to axi-cel for the second-line treatment of primary refractory or early relapsed LBCL.
Read More ›
Year in Review
TRANSFORM Primary Analysis Revealed Improved Outcomes with Liso-cel in the 2L Treatment of Primary Refractory or Early Relapsed LBCL
LBCL 2022 - Year in Review
The primary analysis of the TRANSFORM study comparing liso-cel to standard of care in adults with primary refractory or early relapsed LBCL resulted in achievement of key clinical benefit end points.
Read More ›
Year in Review
Indirect Comparison of Liso-cel and Axi-cel for 2L Treatment of R/R LBCL Revealed Comparable Efficacy with Safety Outcomes Favoring Liso-cel
LBCL 2022 - Year in Review
Matching-adjusted indirect comparison of liso-cel to axi-cel utilizing data from the TRANSFORM and ZUMA-7 studies revealed lower odds of key CAR-T‒associated adverse events with liso-cel.
Read More ›
Year in Review
YTB323 (Rapcabtagene Autoleucel) in R/R DLBCL After ≥2 Lines of Prior Therapy
LBCL 2022 - Year in Review
Phase 1 results of YTB323 in patients with R/R DLBCL demonstrate durable efficacy with a favorable safety profile, as well as identify the recommended phase 2/3 dose.
Read More ›
Year in Review
CIBMTR Registry Analysis Evaluated the Impact of Age on Outcomes in Patients with LBCL Receiving CAR-T Therapy
LBCL 2022 - Year in Review
Data from the CIBMTR registry revealed that advanced age does not impact mortality associated with CAR-T therapy, and that CAR-T therapy is feasible in older adults.
Read More ›
Year in Review
Inflammatory Biomarker Clusters May Provide a New Means for Risk Stratification of Patients with LBCL Receiving CAR-T Therapy
LBCL 2022 - Year in Review
Two distinct inflammatory clusters were identified and found to be tightly linked to response and survival of patients with LBCL receiving CAR-T therapy, with validation utilizing an independent cohort.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
CDK Inhibition in ER-Positive/HER2-Negative Metastatic Breast Cancer: Real-World Evidence of the Risk of Disease Progression on First-Line Treatment
SABCS 2022
No significant differences in PFS were found between abemaciclib, palbociclib, and ribociclib in a real-world setting.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Preoperative Ribociclib and Letrozole versus Chemotherapy in HR-Positive/HER2-Negative Breast Cancer: Findings from a Correlative Analysis of the Phase 2 1402-SOLTI/CORALLEEN Trial Study
SABCS 2022
Ribociclib in combination with letrozole induces potent antiproliferative effects in comparison to chemotherapy in patients with HR-positive/HER2-negative breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Maintenance Ribociclib and ET Following First-Line Chemotherapy in HR-Positive/HER2-Negative Metastatic Breast Cancer: Findings from the Phase 2 AMICA Trial
SABCS 2022
Ribociclib plus ET shows promising efficacy as maintenance therapy in patients with HR-positive/HER2-negative metastatic breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Elacestrant in Postmenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer: Findings from the SOLTI-1905-ELIPSE Trial
SABCS 2022
Preoperative treatment with elacestrant is associated with relevant biological and molecular responses.
Read More ›
Page 10 of 136
7
8
9
10
11
12
13
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us